222 related articles for article (PubMed ID: 16918256)
1. Host defence against disseminated Candida albicans infection and implications for antifungal immunotherapy.
Vonk AG; Netea MG; van der Meer JW; Kullberg BJ
Expert Opin Biol Ther; 2006 Sep; 6(9):891-903. PubMed ID: 16918256
[TBL] [Abstract][Full Text] [Related]
2. Induction of protective Th1 responses to Candida albicans by antifungal therapy alone or in combination with an interleukin-4 antagonist.
Cenci E; Mencacci A; Del Sero G; Fé d'Ostiani C; Montagnoli C; Bacci A; Bistoni F; Romani L
J Chemother; 1998 Apr; 10(2):160-3. PubMed ID: 9603646
[No Abstract] [Full Text] [Related]
3. Modulation of neutrophil function in host defense against disseminated Candida albicans infection in mice.
Kullberg BJ; Netea MG; Vonk AG; van der Meer JW
FEMS Immunol Med Microbiol; 1999 Dec; 26(3-4):299-307. PubMed ID: 10575142
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy: a potential adjunctive treatment for fungal infection.
Kullberg BJ; van de Veerdonk F; Netea MG
Curr Opin Infect Dis; 2014 Dec; 27(6):511-6. PubMed ID: 25304393
[TBL] [Abstract][Full Text] [Related]
5. Looking into Candida albicans infection, host response, and antifungal strategies.
Wang Y
Virulence; 2015; 6(4):307-8. PubMed ID: 25590793
[TBL] [Abstract][Full Text] [Related]
6. Innate immune cell response upon Candida albicans infection.
Qin Y; Zhang L; Xu Z; Zhang J; Jiang YY; Cao Y; Yan T
Virulence; 2016 Jul; 7(5):512-26. PubMed ID: 27078171
[TBL] [Abstract][Full Text] [Related]
7. Silenced suppressor of cytokine signaling 1 (SOCS1) enhances the maturation and antifungal immunity of dendritic cells in response to Candida albicans in vitro.
Shi D; Li D; Yin Q; Qiu Y; Yan H; Shen Y; Lu G; Liu W
Immunol Res; 2015 Mar; 61(3):206-18. PubMed ID: 25381480
[TBL] [Abstract][Full Text] [Related]
8. Vaccination with recombinant N-terminal domain of Als1p improves survival during murine disseminated candidiasis by enhancing cell-mediated, not humoral, immunity.
Ibrahim AS; Spellberg BJ; Avenissian V; Fu Y; Filler SG; Edwards JE
Infect Immun; 2005 Feb; 73(2):999-1005. PubMed ID: 15664943
[TBL] [Abstract][Full Text] [Related]
9. Host immune reactivity determines the efficacy of combination immunotherapy and antifungal chemotherapy in candidiasis.
Mencacci A; Cenci E; Bacci A; Bistoni F; Romani L
J Infect Dis; 2000 Feb; 181(2):686-94. PubMed ID: 10669356
[TBL] [Abstract][Full Text] [Related]
10. Induction of protective Th1 responses to Candida albicans by antifungal therapy alone or in combination with an interleukin-4 antagonist.
Cenci E; Mencacci A; Del Sero G; Bistoni F; Romani L
J Infect Dis; 1997 Jul; 176(1):217-26. PubMed ID: 9207370
[TBL] [Abstract][Full Text] [Related]
11. Ginsenoside Rd induces protective anti-Candida albicans antibody through immunological adjuvant activity.
Han Y; Rhew KY
Int Immunopharmacol; 2013 Nov; 17(3):651-7. PubMed ID: 24007781
[TBL] [Abstract][Full Text] [Related]
12. Cutting edge: Nlrp10 is essential for protective antifungal adaptive immunity against Candida albicans.
Joly S; Eisenbarth SC; Olivier AK; Williams A; Kaplan DH; Cassel SL; Flavell RA; Sutterwala FS
J Immunol; 2012 Nov; 189(10):4713-7. PubMed ID: 23071280
[TBL] [Abstract][Full Text] [Related]
13. Host defence against Candida albicans and the role of pattern-recognition receptors.
Gauglitz GG; Callenberg H; Weindl G; Korting HC
Acta Derm Venereol; 2012 May; 92(3):291-8. PubMed ID: 22170181
[TBL] [Abstract][Full Text] [Related]
14. Ginsenoside Rg1 helps mice resist to disseminated candidiasis by Th1 type differentiation of CD4+ T cell.
Lee JH; Han Y
Int Immunopharmacol; 2006 Sep; 6(9):1424-30. PubMed ID: 16846836
[TBL] [Abstract][Full Text] [Related]
15. Antifungal combination therapy with granulocyte colony-stimulating factor and fluconazole in experimental disseminated candidiasis.
Graybill JR; Bocanegra R; Luther M
Eur J Clin Microbiol Infect Dis; 1995 Aug; 14(8):700-3. PubMed ID: 8565989
[TBL] [Abstract][Full Text] [Related]
16. Host response to Candida albicans bloodstream infection and sepsis.
Duggan S; Leonhardt I; Hünniger K; Kurzai O
Virulence; 2015; 6(4):316-26. PubMed ID: 25785541
[TBL] [Abstract][Full Text] [Related]
17. Adaptive immune responses to Candida albicans infection.
Richardson JP; Moyes DL
Virulence; 2015; 6(4):327-37. PubMed ID: 25607781
[TBL] [Abstract][Full Text] [Related]
18. Thymol has antifungal activity against Candida albicans during infection and maintains the innate immune response required for function of the p38 MAPK signaling pathway in Caenorhabditis elegans.
Shu C; Sun L; Zhang W
Immunol Res; 2016 Aug; 64(4):1013-24. PubMed ID: 26783030
[TBL] [Abstract][Full Text] [Related]
19. Interplay between Candida albicans and the mammalian innate host defense.
Cheng SC; Joosten LA; Kullberg BJ; Netea MG
Infect Immun; 2012 Apr; 80(4):1304-13. PubMed ID: 22252867
[TBL] [Abstract][Full Text] [Related]
20. Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice.
Lin L; Ibrahim AS; Xu X; Farber JM; Avanesian V; Baquir B; Fu Y; French SW; Edwards JE; Spellberg B
PLoS Pathog; 2009 Dec; 5(12):e1000703. PubMed ID: 20041174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
